Cargando…
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
Oral administration of sapropterin hydrochloride, recently approved for use by the US Food and Drug Administration and the European Commission, is a novel approach for the treatment of phenylketonuria (PKU), one of the most common inborn errors of metabolism. PKU is caused by an inherited deficiency...
Autor principal: | Harding, Cary O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921259/ https://www.ncbi.nlm.nih.gov/pubmed/20714359 |
Ejemplares similares
-
Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride
por: Douglas, Teresa D, et al.
Publicado: (2013) -
A Prospective Population Pharmacokinetic Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria
por: Qi, Yulan, et al.
Publicado: (2014) -
Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria
por: Hawks, Zoë, et al.
Publicado: (2017) -
Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta‐analysis of randomized controlled trials
por: Qu, Jinghan, et al.
Publicado: (2019) -
First Japanese case of maternal phenylketonuria treated with sapropterin dihydrochloride and the normal growth and development of the child
por: Nyuzuki, Hiromi, et al.
Publicado: (2019)